Vitestro, a Netherlands-based medical robotics company developing autonomous blood-drawing technology, has raised $70 million in an oversubscribed Series B financing round to accelerate development of its robotic phlebotomy platform and expand commercial readiness. The round drew participation from several new strategic healthcare investors, including Labcorp Venture Fund, Mayo Clinic, and Sutter Health. Additional new financial investors included InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht. Existing investors Invest-NL, the EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital also participated in the financing.
Vitestro plans to use the new capital to advance the next generation of its Aletta Autonomous Robotic Phlebotomy Device, expand clinical studies, and scale manufacturing ahead of broader commercialization. The company is also working through the U.S. FDA De Novo regulatory pathway as it prepares to bring the technology to the U.S. market.
Diagnostic blood collection is the most common invasive medical procedure globally, with billions of blood draws performed each year. Vitestro aims to automate the process using robotics, multimodal imaging, and artificial intelligence to identify veins, guide needle insertion, and collect samples with greater precision and consistency.
The Aletta system is designed to perform routine blood draws in high-volume clinical settings, supporting phlebotomy departments, addressing staffing shortages, and reducing variability associated with manual procedures. The technology is intended to standardize quality, improve patient experience, and increase operational efficiency across outpatient care settings.
Vitestro’s leadership says the funding will also support integration of the system into existing clinical workflows and technology infrastructure while expanding pilot programs and collaborations with healthcare providers.
The company’s Aletta system currently holds a CE mark in Europe and is being deployed in clinical and pre-commercial settings across the region. The device has not yet received FDA authorization in the United States as the company continues to advance its regulatory pathway and global clinical partnerships.
KEY QUOTES:
“Closing our Series B financing reflects strong conviction in our mission to establish a new standard in autonomous robotic venous access and diagnostic blood collection. Our technology has evolved from a novel vision into a clinically validated reality, and we are grateful for the support of this distinguished syndicate of strategic, healthcare, and life science investors as we move toward broad clinical adoption. Diagnostic blood collection remains the highest-volume invasive medical procedure globally, with billions of procedures performed annually.”
Toon Overbeeke, Chief Executive Officer and Co-Founder, Vitestro
“The Labcorp Venture Fund sees strong potential in solutions that modernize core diagnostic processes and improve consistency for patients. Applying robotics, multimodal imaging and AI to clinically validated diagnostic blood collection is an exciting approach, and we’re thrilled to support Vitestro as they advance this important work.”
Megann Vaughn Watters, Head of Labcorp Venture Fund
“Vitestro is redefining one of the largest and most under innovated clinical workflows with a first-of-its-kind autonomous robotic platform for diagnostic blood collection addressing an enormous unmet global market need. I believe this technology has the potential to establish a new standard of care, much as robotic surgery did in its early days.”
Dr. Fred Moll, Co-Founder and Partner, Sonder Capital; Former Co-Founder and CEO, Intuitive Surgical and Auris Health
